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Abstract: Mesenchymal stem cells (MSCs) are multipotent adult cells with self-renewing capacities.
MSCs display specific properties, such as the ability to repair damaged tissues, resulting in
optimal candidates for cell therapy against degenerative diseases. In addition to the reparative
functions of MSCs, growing evidence shows that these cells have potent immunomodulatory and
anti-inflammatory properties. Therefore, MSCs are potential tools for treating inflammation-related
neurological diseases, including epilepsy. In this regard, over the last decades, epilepsy has no longer
been considered a purely neuronal pathology, since inflammatory events underlying the genesis of
epilepsy have been demonstrated. This review assessed current knowledge on the use of MSCs in the
treatment of epilepsy. Mostly, attention will be focused on the anti-inflammatory and immunological
skills of MSCs. Understanding the mechanisms by which MSCs might modulate the severity of the
disease will contribute to the development of new potential alternatives for both prophylaxis and
treatment against epilepsy.
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1. Mesenchymal Stem Cells
Mesenchymal stem cells (MSCs) are multipotent adult stem cells with self-renewal abilities,
which can differentiate into different lineages of mesenchymal tissue, including chondrocytes,
osteoblasts, and adipocytes [1,2]. Studies suggest that under certain conditions, both experimental
and physiological, MSCs may also be able to differentiate into further cell types, including neurons,
cardiomyocytes, and endothelial cells [3–5]. MSCs can be found in almost all tissues, but the most
well-known sources of MSCs are the bone marrow and the vascular fraction of adipose stroma; in recent
decades, the placenta and the umbilical cord have also been identified as excellent sources of MSCs [6].
Whatever the source, MSC collection does not raise ethical concerns and cultures can be reliably
obtained and maintained [7]. MSCs are characterized by a fibroblast-like morphology and are easily
distinguished from hematopoietic stem cells thanks to their strong adherence to standard culture
dishes and their marker expression pattern. Specifically, they are generally positive for CD90, CD73,
and CD105 and negative for the hematopoietic markers CD45, CD34, CD79a or CD19, CD14 or CD11b,
and human leukocyte antigen DR [8].
Although the in-vitro phenotype of MSCs is well-known, understanding their physiology in vivo
has been made difficult by the lack of specific markers. Recent advances in murine research, however,
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may provide new tools for evaluating the role of MSCs in physiological conditions. Specifically,
recent studies have demonstrated that MSCs provide a perivascular niche for hematopoietic stem
cells and regulate their trafficking, along with those of immune cells. It has also been suggested that
the MSC function depends on the tissue context and molecular signals, which could induce MSCs to
release cytokines and chemokines, with either pro-inflammatory or anti-inflammatory effects [1,9,10].
2. MSCs and Mechanisms of Action
MSCs have been regarded as promising agents for regenerative medicine, due to their self-renewal
and multilineage differentiation capacity [11,12]. In recent years, in-vitro studies have shown that,
besides their ability to differentiate into distinct cell types, MSCs may also exert therapeutic effects by cell
“enhancement”, through the release of trophic and anti-inflammatory factors, which may re-establish
the physiological environment. Indeed, MSCs also have a modulatory role in the inflammatory and
immune response. Based on these features, MSCs have been employed as therapeutic tools in a variety
of clinical conditions other than regenerative medicine, including autoimmune and inflammatory
disorders [13–17].
A large body of work shows that, following cell or tissue injury, MSCs can activate by inflammatory
cytokines, move to the damage site, and control the tissue-regeneration process by releasing an array
of factors that may facilitate the differentiation and proliferation of progenitor cells while inhibiting
inflammatory responses [18]. The secreted factors include cytokines, such as interleukin (IL)-10 and
growth factors (GF), including stromal cell-derived factor-1 (SDF-1), epidermal GF (EGF), keratinocyte
GF (KGF)-1, fibroblast GF (FGF), vascular endothelial GF (VEGF), plated-derived GF (PDGF), hepatocyte
GF (HGF), transforming growth factor (TGF)-β, and insulin GF (IGF)-1 [19]. The exact mechanisms by
which MSCs are recruited and activated at the damage site are still unclear (Figure 1) [20,21].
Figure 1. Schematic of the putative mechanisms of action of mesenchymal stem cell (MSC) therapy in
neurological diseases. (A) Neurological challenges, such as infections, head trauma, and autoimmune
diseases, may lead to brain injury, characterized by a release of proinflammatory cytokine. However,
even peripheral organ damage may upregulate the levels of proinflammatory cytokines in circulating
blood, finally reaching the brain throughout systemic circulation. Once circulating cytokines interact
with a neuro-vascular unit, the neuronal excitability threshold is lower and electrical paroxysmal
events may happen, leading to a possible alteration of the local neuronal circuitry. (B) When MSCs
are administered peripherally, (C) a smaller part is directly mobilized to the site of injury, while (D)
most cells get trapped in organs such as the liver, lungs, lymph nodes, and spleen. (E) Here, MSCs are
activated by inflammatory mediators and release paracrine factors and microvesicles in the bloodstream.
(F) These molecules reach the site of injury, and, together with MSCs previously recruited, modulate the
progression of inflammation and facilitate tissue repair.
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We do know that most peripherally-administered MSCs reach, and are potentially trapped in,
organs such as the spleen, lungs, liver, and lymph nodes, making the rates of MSC engraftment quite
poor [22,23]. Recent evidence has shown the effectiveness of secretome- or MSC-conditioned medium
(CM) in preclinical studies in view of its therapeutic potential in pathologies such as gastric mucosal
injury, colitis, and cardiovascular diseases [24–26] Moreover, it has been demonstrated that MSCs are
also capable of releasing exosomes and microvesicles, which could have biological properties similar
to those possessed by whole MSCs. Therefore, MSC-derived extracellular vesicles could be used as
an alternative MSC-based therapy with a superior safety profile [27]. Taken together, the evidence
points to a hypothetical paracrine mechanism for anti-inflammatory and immunomodulatory MSCs’
properties [28,29].
3. MSC and Mechanisms of Action in Inflammation
Recently, significant advances have been made in understanding the mechanisms underlying
the immunomodulatory and anti-inflammatory properties of MSCs. In-vitro studies show that MSCs
may respond in opposite directions, depending on the intensity of environmental signals. Namely,
they appear to promote inflammation when the immune system is underactivated and suppress it
when the immune system is overactivated [30,31]. At the early stages of inflammation, MSCs sense
pro-inflammatory signals through receptors for IL-1β, interferon (IFN)-γ, Toll-like receptors, and tumor
necrosis factor (TNF)-α, and enhance inflammation. They promote T-cell activation by secreting
chemokines, including the C-X-C motif ligand (CXCL)9, macrophage inflammatory protein-1, CCL5,
and CXCL10, and recruiting more lymphocytes. At this stage, the low levels of inflammatory signals,
such as TNF-α and IFN-γ, are sufficient to upregulate their chemokine secretion, but not to induce a
significant expression of immunomodulatory mediators, such as inducible nitric oxide synthase (iNOS)
in mice or indoleamine 2,3-dioxygenase (IDO) in humans [32].
At later stages, higher levels of pro-inflammatory factors, such as IL-1β, IFN-γ, and TNF-α,
stimulate MSCs to reduce inflammation and avoid autoimmune reactions by releasing, for example,
TGF-β, IL-10, IDO, or iNOS, resulting in an inhibition of the migration, maturation, and antigen
presentation of dendritic cells (DC), and of T-cell function and proliferation [33,34], along with the
proliferation of regulatory T cells [30,35]. Therefore, the IDO or iNOS level has been proposed as the
switcher between the pro- and anti-inflammatory effects of MSCs [36].
Moreover, MSCs have been shown to provide in-vitro immunosuppressive activities on activated
B cells. Specifically, MSCs decrease B-cell proliferation by arresting their cell cycle and affect B-cell
differentiation, as immunoglobulin (Ig) M, IgG, and IgA production are diminished [37]. A wealth
of data suggests the role of MSCs in the induction of regulatory B cells [38]. More recent evidence
shows that human MSC-treated regulatory CD23+ CD43+ B cells erase intestinal inflammation [39]
and human umbilical cord-derived MSCs defend against colitis via CD5+ regulatory B cells [40].
Therefore, MSCs may suppress inflammation processes in different ways, through the upregulation of
anti-inflammatory factors or the downregulation of proinflammatory factors. In addition, MSCs may
also suppress immune reactions via direct cell contact.
4. Epilepsy
Epilepsy is a chronic neurological condition affecting over 50 million people worldwide, with about
5 million people diagnosed with epilepsy every year [41,42]. Epilepsy is defined as a brain pathology
characterized by recurrent, unprovoked epileptic seizures and is related to a variety of neurological
diseases and other medical conditions [43]. It is estimated that around 60% of patients diagnosed
with epilepsy have focal epilepsy, and among these, temporal lobe epilepsy (TLE) is the main cause of
refractory epilepsy [44].
Although both environmental and genetic factors contribute to individual predisposition to
epilepsy, in most cases, its physiopathology is still unknown [45]. Nowadays, the first-line therapeutic
approach is pharmacological, based on anti-seizure medications that act by reducing the neuronal
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excitability, either through an inhibition of sodium ion channels or by enhancing the activity of
γ-aminobutyric acid (GABA) receptors. However, almost 30% of patients are refractory to these
therapies. Additionally, anti-seizure medications may have side effects in several patients, and provide
a purely symptomatic treatment, without acting on epileptogenesis mechanisms [46,47]. For these
reasons, it is extremely important to develop alternative therapeutic approaches.
Recently, new experimental treatment approaches have been explored, including microRNA
silencing [48], gene therapy, and neural cell transplantation. In particular, the goal of the latter
two approaches is to recreate damaged circuits, enhance the inhibitory response through the replacement
of GABAergic neurons, and increase anti-inflammatory mediators and trophic factors respectively
produced by microglia and astrocytes [49]. However, these approaches have limitations, including a
delay in gene expression after transfection or the need to perform transplantation at multiple sites,
given the multiple brain areas where an epileptic status can occur. An alternative method would be to
use pluripotent stem cells; however, these are not yet ready to be handled in clinical studies, given the
high probability of developing a teratoma and triggering immunological complications [50].
MSC transplantation, on the other hand, appears to be a promising treatment for some neurological
disorders, including epilepsy [51]. Indeed, some of the distinctive features of MSCs make them excellent
candidates for this purpose. These properties include a high homing potential, a limited probability of
developing teratomas, renewal and regeneration expertise and, most importantly, anti-inflammatory
properties [52]. In particular, the immunomodulatory and anti-inflammatory properties of MSCs
represent an opportunity for future research on the treatment of epilepsy. In the last few years,
evidence from both preclinical and clinical studies has suggested that inflammation might be both a
consequence and a cause of epilepsy [53].
5. MSCs and Epilepsy
Due to their intrinsic properties, MSCs have been proposed as a safe and promising asset for the
treatment of epilepsy in the pre-clinical setting [54]. In most cases, refractory temporal lobe epilepsy
is associated with hippocampal sclerosis, aberrant mossy fiber sprouting, and the loss of neurons.
Therefore, MSCs were initially tested to treat epilepsy by repairing and/or regenerating damaged
tissues. In particular, several preclinical studies were carried out to test the ability of MSCs to reduce
epileptogenesis, which is the process by which a brain network is functionally altered by an increased
seizure susceptibility, thus enhancing the probability to generate spontaneous recurrent seizures [55].
In these studies, MSCs were injected in several animal models of epilepsy, either intravenously or
directly in the hippocampus. While the results were sometimes comparable (see below), some studies
suggested that MSCs have the best therapeutic effect when they are directly injected in the central
nervous system [56].
An intravenous infusion of MSCs in a rat lithium-pilocarpine injection model of temporal lobe
epilepsy has been shown to reduce epileptogenesis and preserve cognitive function by inhibiting
neuronal cell death and decreasing aberrant mossy fibers of the hippocampus [54]. Further studies
have shown that the intravenous administration of bone marrow stromal cells reduced the number of
seizures and preserved neurons from death and neurophagia in a rat pilocarpine or lithium-pilocarpine
model of TLE [57–59]. Using the same animal model, MSCs injected in the right hippocampus
reduced the amplitude and frequency of electroencephalographic spike-waves and improved the
dysregulated adenosine receptor expression that accompanied experimentally-induced epilepsy
in rats [60]. Similarly, intra-hippocampal injections of human umbilical mesenchymal stem cells
(HUMSCs) attenuated the incidence and duration of spontaneous recurrent seizures in a rat pilocarpine
TLE model. The mechanisms underlying these effects include a reduction of mossy fiber sprouting,
a decrease of neuron and interneuron loss, and the suppression of status epilepticus (SE)-induced brain
inflammation [61].
Another study revealed that the intranasal administration of extracellular MSC-derived vesicles
reduced SE-induced neuroinflammation, cognitive dysfunction, and aberrant neurogenesis in a
Int. J. Mol. Sci. 2020, 21, 9683 5 of 15
mouse pilocarpine model of epilepsy [62]. In-vitro studies have shown that the ability of MSCs
to reduce epileptogenesis is partially due to their capacity to protect neurons against glutamate
excitotoxicity. It has been suggested that this protection is associated with a reduced expression of
N-methyl-D-aspartate receptor subunits and glutamate-induced Ca2+ responses [63].
Additionally, MSC culture medium decreases levels of the GluR1 subunit of the AMPA receptor
on the neural cell surface, thus reducing neuronal glutamate signaling [64].
Genetically engineered bone marrow MSCs have also been proposed: The silencing of Hes1,
which is a gene involved in the neural differentiation of bone marrow stem cells, has been proven to
promote the differentiation of these cells into GABAergic neuron-like cells, improving the functional
outcome in a rat model of epilepsy [65].
The silencing of Hes1 in bone marrow stem cells has been shown to promote their differentiation
into GABAergic neuron-like cells [65]. The use of genetically engineered bone marrow MSCs in
a lithium-pilocarpine rat model of epilepsy resulted in a functional improvement. Benefits were
proportional to the degree of cell differentiation [65].
Currently, only a single clinical study regarding the use of MSCs in epilepsy treatment has been
published. This study, not registered on NIH ClinicalTrials.gov, demonstrated that therapy with
autologous MSC decreases the number of seizures in electroencephalography evaluation and leads to
cognitive improvements in children with drug-resistant epilepsy. Moreover, the results do not show
early or late side effects associated with the transplantation procedure or the therapy itself [66].
6. Role of Inflammation in the Pathogenesis of Epilepsy
Historically, epilepsy was considered a “neuron-centered” disease. Recent studies have revealed
that the neuronal activity itself depends on the close interactions between neurons, glial cells,
the blood–brain barrier (BBB) permeability, the vascular endothelium, immune-related blood cells,
and a “humoral network” of diffusible factors that includes various cytokines and chemokines.
From this perspective, the neurovascular unit is regarded as an extremely important complex for
understanding the pathogenesis of epilepsy [67], especially with regards to the recently emerged role of
inflammation in epileptogenesis. A growing body of literature suggests that inflammatory mechanisms
play an important role in the development and progression of seizure activity. Conversely, seizures can
induce inflammation of the brain and their recurrence may lead to chronic inflammation (Figure 2) [68].
Either prolonged or focal febrile seizures in childhood have been associated with an increased risk
of developing an intractable form of temporal lobe epilepsy [69]. Another clinical study showed that
febrile seizures raise the levels of pro-inflammatory cytokines IL-6, TNF-α, and IL-1β in cerebrospinal
fluid [70]. Furthermore, human brain tissue obtained during the surgical resection of the seizure focus
in patients with refractory focal epilepsy expressed significantly more biomarkers of inflammation
than samples from non-epileptic patients [71].
In-vitro and in-vivo research models allow in-depth investigations of the inflammatory processes
that can trigger (or be triggered by) seizure activity. Increasing evidence supports the existence of a
complex interplay between systemic inflammatory processes and brain homeostasis. For example,
autoimmune diseases or common infections can predispose to spontaneous recurrent seizures [72].
Interestingly, when the lipopolysaccharide, which is a component of Gram-negative bacteria,
was administered chronically in rats, an increased permeability of the BBB was observed as a
consequence of the systemic inflammation [73]. Therefore, the interplay between the peripheral
immune response and the central nervous system may play a role in the development of seizures and
ultimately, epilepsy.
Nevertheless, an increasing number of clinical and preclinical studies have revealed that
inflammation may play a role in seizure susceptibility, even without immune-mediated pathologies
or infections. An increase in TNF, IL-6, IL-1β, and the IL-1 receptor antagonist has been found in
blood serum and cerebrospinal fluid in patients with chronic epilepsy after seizures [74]. Similarly,
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VEGF, TGF-β1, IL-6, IL-1β, and TNF-α upregulated their mRNA expression in the hippocampus after
seizures [75].
Figure 2. Cascade of events during inflammation-mediated seizures. (A) An initiating inflammatory
challenge causes an increase of proinflammatory mediators such as cytokines and chemokines, (B) which
in turn leads to an upregulation of leukocyte ligands (e.g., LFA-1) and endothelial counterligands
(e.g., ICAM-1), eventually resulting in leukocyte recruitment. (C) Upregulation of adhesion molecules
reflected in leukocyte migration into the brain parenchyma and (D) a morphological change in the
endothelial cells’ shape, finally resulting in an alteration of tight junctions; these processes will lead
to blood–brain barrier (BBB) leakage with the extravasation of serum components (e.g., albumin).
(E) Microglial cells are consequently activated by proinflammatory cytokines. (F) Moreover, the albumin
extravasation induces a decrease of inward-rectifying K+ channels in astrocytes, leading to an increase
of extracellular potassium in brain parenchyma. (G) Therefore, the higher extracellular K+ level
facilitates neuronal hyperexcitability and induces seizure activity.
7. BBB Permeability and Inflammation in Epilepsy
Increasing evidence, from both research models and human specimens, suggests that
leukocyte–endothelial interaction mechanisms may play an important role in the pathogenesis
of epilepsy. It was shown that leukocyte trafficking mechanisms promote BBB leakage, which led to
seizure activity [76]. Moreover, patients with different types of epilepsy exhibited higher numbers of
leukocytes in brain parenchyma compared to control patients [77]. Along with leukocyte migration
through BBB, albumin extravasation has been suggested to be involved in epileptogenesis.
Indeed, extravasated albumin was found to induce epileptogenesis binding TGF receptor 2 in
astrocytes. This results in astrocytic transformation and dysfunction, characterized by a downregulation
of inward-rectifying K+ channels, interfering with the physiological buffering of extracellular K+ ions
by astrocyte. Therefore, the increased availability of K+ ions in the extracellular compartment facilitates
neuronal hyperexcitability, and eventually induces epileptiform activity [78,79].
8. MSCs and Inflammation in Epilepsy
Cell therapies with MSCs have been proposed as a possible treatment for inflammatory
diseases [16,17]. This has suggested that, in addition to neuroprotection and the reshaping of neuronal
circuits, the therapeutic mechanism of MSCs in treating epilepsy might also include immunomodulation
and an anti-inflammatory pathway. As mentioned above, seizures can cause brain damage and
consequently, a loss of neurons, but not all seizures seem to cause structural lesions detectable by
magnetic resonance imaging [80]. On the other hand, epileptic seizures cause an inflammatory response
and a consequent immunological reaction [81]. Therefore, MSCs are likely to act via the release of
cytoprotective, immunomodulatory, and anti-inflammatory factors that can contribute to the recovery
and rebalancing of damaged tissues (Figure 3) [36].
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Figure 3. The putative effects of MSC therapy on the inflammatory cascade of events during seizures.
(A) MSCs downregulate adhesion molecule (e.g., ICAM-1) expression. (B) MSCs inhibit leukocytes by
blocking their pro-inflammatory factor expression, resulting in decreasing levels of proinflammatory
cytokine and leukocyte cell recruitment at the site of damage. (C) MSCs release various factors
(e.g., KGF, EGF, VEGF and PDGF), involved in maintaining endothelial integrity and preventing
interactions between leukocytes and endothelial cells. (D) In addition, MSCs promote the switching of
microglia from a pro-inflammatory (type 1) to an anti-inflammatory (type 2) phenotype, thus increasing
the level of anti-inflammatory cytokines (IL-4 and IL-10). Anti-inflammatory cytokines reduce
inflammation by suppressing microglia and T cell activation, pro-inflammatory cytokine production,
and leukocyte recruitment.
An intravenous administration of bone marrow mononuclear cells (BMMCs), which is a
heterogeneous population comprised of both stem cells and progenitor cells with potential therapeutic
value, in an animal model of TLE, resulted in a decrease of cell death and inflammatory mediators,
without any differentiation of BMMCs into neurons [82]. Since the success of MSC-based therapy
does not correlate with the efficiency of cell replacement and engraftment, it is thought that the
anti-inflammatory and neuroprotective MSCs’ properties are mainly exercised throughout paracrine
mechanisms [83,84]. However, since MSCs were found in the hippocampus after intravenous
administration, it is also possible that MSCs migrate directly into the brain to exert their effect [54].
As previously mentioned, evidence from both preclinical animal models and clinical studies
suggests that inflammation might be both a consequence and a cause of epilepsy. Moreover,
epileptic seizures generate a pro-inflammatory milieu by raising the levels of IL-6, TNF-α, and IL-1β
in the hippocampus and cerebrospinal fluid [70,85]. This environment attracts MSCs at the sites of
injury where they are licensed to exert their immunomodulatory purposes. Therefore, MSCs could
respond to excessive proinflammatory signals, such as through their receptors for IL-1β, IFN-γ,
and TNF-α. To exercise their anti-inflammatory and immunosuppressive functions, MSCs need to
be stimulated by IFN-γ, in combination with one (or more) proinflammatory cytokines (TNF-α, IL-6,
IL1-β, or IL-1α). Therefore, MSCs could respond to excessive proinflammatory signals, by releasing a
burst of anti-inflammatory cytokines, chemokines, and a high level of immunosuppressive factors [32].
It has been reported that, in animal models of epilepsy, BMMC therapy increased the level of
anti-inflammatory cytokines (IL-4 and IL-10) and decreased proinflammatory cytokine levels (IL-6,
Il-1β, and TNF-α) in the brain and blood serum [82]. Moreover, bone marrow mononuclear cell
transplantation reduced gliosis and neural loss [58].
MSCs may release various factors, such as Angiopoietin 1, VEGF, HGF, KGF, EGF, PDGF, FGF,
and TGF-β, which directly influence endothelial cells. These paracrine trophic factors are important in
maintaining endothelial integrity and promoting angiogenesis through the regulation of endothelial cell
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proliferation, reduction of endothelial permeability, and prevention of interactions between leukocytes
and endothelial cells [86].
8.1. MSCs and Lymphocytes
As previously stated, leukocyte–endothelial interaction has been demonstrated to play a key role
in the epileptogenic process. The inhibition of leukocyte–vascular interactions markedly reduced
seizures in a mouse model of TLE. Lymphocytes have been demonstrated to be the principal actors
of the inflammatory response, even if neutrophil depletion can also be protective [76]. Regarding
lymphocytes, the Th1, but not Th2, phenotype appears to be recruited at the site of injury after seizures.
This indicates that Th1 immune cells play a key role in the induction of inflammation, thus contributing
to the progression of epilepsy [76].
MSCs are known to induce the differentiation and maturation of Th2 cells through IDO expression,
resulting in the depletion of tryptophan and the accumulation of its metabolites, which eventually induce
Th1 cell apoptosis [87]. Moreover, MSC inhibits Th1 cells directly by blocking their pro-inflammatory
factor expression, or indirectly through the suppression of DC and NK cells [88]. This evidence might
suggest that one of the mechanisms by which MSCs may suppress inflammation in epilepsy is the
decrease of Th1 cell recruitment at the site of damage.
Recent studies have revealed that the blockage of leukocyte–vascular adhesion prevented BBB
disruption in animal models of epilepsy [76]. It has been demonstrated that MSCs are able to
downregulate intercellular adhesion molecule 1 (ICAM-1) expression both in vivo and in vitro [89].
ICAM-1 is an endothelial cell adhesion molecule directly involved in sustaining leukocyte adhesion
and BBB integrity; a downregulation of ICAM-1 activation has been demonstrated to play a protective
role in epileptogenesis [76]. Currently, it is still unclear which factors are secreted by MSCs to decrease
ICAM-1 expression in endothelial cells.
8.2. MSC and Glial Cells
In addition, MSCs promote the switching of macrophages from a pro-inflammatory (type 1)
to an anti-inflammatory (type 2) phenotype. In addition, in-vitro studies demonstrate that MSCs,
driven by inflammatory signals, enhance phenotypic and functional changes on microglia/macrophages.
In particular, MSCs, through the release of CX3CL1, may promote the switching of microglia
from pro-inflammatory (type 1) to anti-inflammatory (type 2), and increase intracellular calcium
concentrations and phagocytic activity [90]. Since SE leads to type 1 macrophages/microglia activation,
MSCs may also contribute to reducing inflammation in this direction [82,91].
Neuroinflammation may induce different subtypes of reactive astrocytes, which exhibit a
microglia-like phenotype, referred to as A1 (pro-inflammatory) and A2 (anti-inflammatory). The A1
astrocytes lack the main normal astrocyte function, being destructive to synapsis and neurotoxic to
neurons [92].
Since astrocyte alterations are involved in the progression of epilepsy [93], protecting astrocyte
from inflammatory stimuli could be a promising therapeutic strategy. In this regard, it has recently
been demonstrated that MSC cell-derived exosomes could attenuate the A1 astrocytic activation in an
animal model of TLE by regulating the Nrf2-NF-KB signaling pathway [94].
9. Perspectives
The simplicity in obtaining MSCs from both autogenic and allogenic sources, relative lack of
serious adverse outcomes, and relatively non-invasive routes of administration make them attractive
for preclinical and clinical applications. Indeed, the promising features of MSCs, in particular their
immune-regulatory and anti-inflammatory properties, have raised strong interest among researchers
in the field of epilepsy.
As has been demonstrated in various animal models of SE and chronic TLE, MSCs derived from
multiple sources can reduce epileptogenesis and improve cognitive function, which raises the possibility
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of clinical applications, ideally including anti-epileptogenetic treatments in refractory status epilepticus
and drug-resistant epilepsies. Therefore, the approach could overcome the shortcomings of currently
available drug and surgical treatments.
Although preclinical studies have consistently shown the efficacy of MSCs in halting the
progression of epilepsy, only two clinical trials have evaluated their effect in treating epilepsy
in human patients. Both clinical trials are available on www.clinicaltrials.gov [95] but, as of this writing,
final results have not been posted by either study. Standardization may represent a significant obstacle
in obtaining consistent clinical trial results [96]. For example, cultured MSCs differ in behavior and
marker expression, depending on species (mouse vs. human) and animal strains [97]. Given the
importance of species differences for the significance of rodent-based studies as models of human
disease, humanized MSCs have been created by incorporating the human IDO gene into MSCs derived
from mice lacking the Nos2 (iNOS) gene (iNOS−/−). These humanized MSCs show immunomodulatory
effects similar to those of normal human MSCs and thus represent a precious mouse model with which
to mimic the human system [98]. Moreover, MSCs derived from different tissues have different growth
abilities and phenotypic heterogeneity [99]. Finally, differences in funding and legislation might also
be taken into account [100,101].
Therefore, to validate MSC-based therapy as a potential treatment for neurological disease,
discussions on shared guidelines, cost coverage, and legislation support are required. Moreover,
despite the quite extensive knowledge of in-vitro MSC functions, their in-vivo properties and potential
clinical application have yet to be thoroughly investigated. To achieve this purpose, new specific
markers allowing the in-vivo tracing of MSCs are required. Despite current limitations in clinical
practice, in the last few years, several studies have provided new knowledge about the function of
MSCs, especially within inflammation. It has become clear that the reparative ability of MSCs depends
on the strength of the inflammation process. Therefore, MSCs may have different responses and
growth-factor production to different levels of inflammation, cytokines, and immunosuppressants.
Deepening our understanding of the plasticity of MSC-mediated immune regulation, together with the
abovementioned adjustments, will help to improve the accuracy of MSC treatment, in order to achieve
clinical relevance in the near future.
10. Conclusions
MSCs, as well as other types of stem cells, offer a potential tool for treating inflammatory
diseases, including epilepsy. It seems that MSCs reduce epileptogenesis by means of trophic and
anti-inflammatory factor release. Therefore, these secreted factors interact with cells of both immune
and central nervous systems, contributing to restoring the neuronal homeostasis in affected areas.
However, our knowledge is still inadequate for an immediate application of MSCs in clinical procedures
for epilepsy’s treatment.
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ICAM-1 Intercellular Adhesion Molecule 1
Ig Immunoglobulin
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IL Interleukin
IFN Interferon
MSCs Mesenchymal Stem Cells
SE Status Epilepticus
TGF Transforming Growth Factor
TLE Temporal Lobe Epilepsy
Th T helper
TNF Tumor Necrosis Factor
VEGF Vascular Endothelial Growth Factor
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